The number of people living with neurological disorders, such as Alzheimer’s disease, epilepsy, multiple sclerosis and ...

MS patients who achieve long-term stable disease on disease-modifying therapy may want to stop their medication for varying ...

FDA issues new warnings about rare but severe allergic reactions, including anaphylaxis, linked to MS drug glatiramer acetate, urging immediate medical attention.

TG Therapeutics is entering 2025 with investors accustomed to a beat-and-raise guidance policy and the company needs to ...

Overall, women with MS have a 26% increased risk of mental illness during pregnancy and a 33% increased risk after giving birth, compared to women without the degenerative nerve disease.

The drugs’ active ingredient, glatiramer acetate, has been linked to more than 80 cases of anaphylaxis worldwide since ...

Teva Pharmaceutical’s Copaxone was approved by the FDA in 1996 to treat relapsing forms of MS, an autoimmune disorder that ...

This report covers recent health news, including Robert F. Kennedy Jr.'s legal fees from Merck litigations, rejections of a ...

Pregnant people with multiple sclerosis (MS) have a higher chance of experiencing mental illness both during their pregnancy and in the first years after they give birth than those without MS, ...

The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.

Recent news highlights include Hong Kong shareholders rejecting Fosun's buyout of Henlius Biotech, Abbott focusing on glucose monitors amidst currency woes, FDA warning on multiple sclerosis drugs, ...

The FDA has advised health care professionals and patients with multiple sclerosis that treatment with glatiramer acetate is ...